Mar 29, 2022 / 08:00PM GMT
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Great. Thanks very much, everyone, for joining in this later afternoon panel with Sage Therapeutics. With me is CEO, Barry Greene, who I'm sure everyone listening in knows well. Barry, assuming everyone knows Sage well, maybe you can just offer some introductory remarks, a couple of high-level updates, and we can get into Q&A. Does that work?
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
Yes. Sounds great, Paul. And I just want to thank you and Stifel for having us here today.
Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Awesome. So please.
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
Yes, please. So thank you. Look, as all of you know, at Sage, we've developed deep expertise in
SAGE Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers